Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country
Abstract Breast cancer (BC) patient-derived xenografts (PDX) are relevant models for precision medicine. However, there are no collections derived from South American BC patients. Since ethnicity significantly impacts clinical outcomes, it is necessary to develop PDX models from different lineages....
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-86389-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594736465051648 |
|---|---|
| author | Gabriela Pataccini Andrés Elia Gonzalo Sequeira Luisa Ambrosio Marcela Coianis Caroline A. Lamb Paola A. Rojas Paula Martínez Vázquez Javier Burruchaga Eunice Spengler Silvia I. Vanzulli Martin Abba Claudia Lanari |
| author_facet | Gabriela Pataccini Andrés Elia Gonzalo Sequeira Luisa Ambrosio Marcela Coianis Caroline A. Lamb Paola A. Rojas Paula Martínez Vázquez Javier Burruchaga Eunice Spengler Silvia I. Vanzulli Martin Abba Claudia Lanari |
| author_sort | Gabriela Pataccini |
| collection | DOAJ |
| description | Abstract Breast cancer (BC) patient-derived xenografts (PDX) are relevant models for precision medicine. However, there are no collections derived from South American BC patients. Since ethnicity significantly impacts clinical outcomes, it is necessary to develop PDX models from different lineages. Our goals were to a) develop BC PDX from our population; b) characterize the expression of estrogen (ER), progesterone (PR), androgen (AR) and glucocorticoid (GR) receptors, basal and luminal cytokeratins, EGFR and HER2; c) identify PDX mutations; d) evaluate the response to treatments selected based on their biological and genetic features, and e) perform BC tissue cultures (BCTC) from PDX tissues and compare in vivo and ex vivo results. Surgical fragments were maintained in a culture medium and inoculated subcutaneously into untreated NSG female mice, or treated with estradiol pellets. Other fragments were fixed in formalin for diagnosis and immunohistochemistry, and a third piece was frozen at -80°C for molecular studies or whole exome-sequencing. Tumors were serially transplanted into NSG mice. Once the PDX was established, in vivo and ex vivo drug responses were evaluated. Eight PDX were established: two ER + [BC-AR685 (PR +) and BC-AR707 (PR-)], one from a triple-negative (TN) recurrence whose primary tumor was ER + (BC-AR485), one HER2 + (BC-AR474) and four TN primary tumors (BC-AR553, BC-AR546, BC-AR631 and BC-AR687). BC-AR685 had higher levels of PR isoform A than isoform B and was sensitive to mifepristone, tamoxifen, and palbociclib. BC-AR707 was inhibited by tamoxifen and testosterone. BC-AR474 was inhibited by trastuzumab and trastuzumab emtansine. BC-AR485 was sensitive to doxorubicin and resistant to paclitaxel in vivo and ex vivo. BC-AR687 carried a PIK3CA (C420R) mutation and was sensitive to alpelisib and mTOR inhibitors. All PDX expressed AR with varying intensities. GR and AR were co-expressed in the ER + tumors and in 3 TN PDX. We report the first PDX originated from South American countries that were genetically and biologically characterized and may be used in precision medicine studies. PDX expressing AR and/or GR are powerful tools to evaluate different endocrine treatment combinations even in TN tumors. |
| format | Article |
| id | doaj-art-028e17062e0341f1ab1644a2f4ba9412 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-028e17062e0341f1ab1644a2f4ba94122025-01-19T12:20:49ZengNature PortfolioScientific Reports2045-23222025-01-0115111610.1038/s41598-025-86389-xSteroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American countryGabriela Pataccini0Andrés Elia1Gonzalo Sequeira2Luisa Ambrosio3Marcela Coianis4Caroline A. Lamb5Paola A. Rojas6Paula Martínez Vázquez7Javier Burruchaga8Eunice Spengler9Silvia I. Vanzulli10Martin Abba11Claudia Lanari12Laboratory of Hormonal Carcinogenesis, IBYME-CONICET, Ciudad Autónoma de Buenos Aires (CABA)Laboratory of Hormonal Carcinogenesis, IBYME-CONICET, Ciudad Autónoma de Buenos Aires (CABA)Laboratory of Hormonal Carcinogenesis, IBYME-CONICET, Ciudad Autónoma de Buenos Aires (CABA)Laboratory of Hormonal Carcinogenesis, IBYME-CONICET, Ciudad Autónoma de Buenos Aires (CABA)Laboratory of Hormonal Carcinogenesis, IBYME-CONICET, Ciudad Autónoma de Buenos Aires (CABA)Laboratory of Hormonal Carcinogenesis, IBYME-CONICET, Ciudad Autónoma de Buenos Aires (CABA)Laboratory of Hormonal Carcinogenesis, IBYME-CONICET, Ciudad Autónoma de Buenos Aires (CABA)Hospital de Agudos Magdalena V. de Martínez, General PachecoHospital de Agudos Magdalena V. de Martínez, General PachecoHospital de Agudos Magdalena V. de Martínez, General PachecoAcademia Nacional de MedicinaUniversidad Nacional de La PlataLaboratory of Hormonal Carcinogenesis, IBYME-CONICET, Ciudad Autónoma de Buenos Aires (CABA)Abstract Breast cancer (BC) patient-derived xenografts (PDX) are relevant models for precision medicine. However, there are no collections derived from South American BC patients. Since ethnicity significantly impacts clinical outcomes, it is necessary to develop PDX models from different lineages. Our goals were to a) develop BC PDX from our population; b) characterize the expression of estrogen (ER), progesterone (PR), androgen (AR) and glucocorticoid (GR) receptors, basal and luminal cytokeratins, EGFR and HER2; c) identify PDX mutations; d) evaluate the response to treatments selected based on their biological and genetic features, and e) perform BC tissue cultures (BCTC) from PDX tissues and compare in vivo and ex vivo results. Surgical fragments were maintained in a culture medium and inoculated subcutaneously into untreated NSG female mice, or treated with estradiol pellets. Other fragments were fixed in formalin for diagnosis and immunohistochemistry, and a third piece was frozen at -80°C for molecular studies or whole exome-sequencing. Tumors were serially transplanted into NSG mice. Once the PDX was established, in vivo and ex vivo drug responses were evaluated. Eight PDX were established: two ER + [BC-AR685 (PR +) and BC-AR707 (PR-)], one from a triple-negative (TN) recurrence whose primary tumor was ER + (BC-AR485), one HER2 + (BC-AR474) and four TN primary tumors (BC-AR553, BC-AR546, BC-AR631 and BC-AR687). BC-AR685 had higher levels of PR isoform A than isoform B and was sensitive to mifepristone, tamoxifen, and palbociclib. BC-AR707 was inhibited by tamoxifen and testosterone. BC-AR474 was inhibited by trastuzumab and trastuzumab emtansine. BC-AR485 was sensitive to doxorubicin and resistant to paclitaxel in vivo and ex vivo. BC-AR687 carried a PIK3CA (C420R) mutation and was sensitive to alpelisib and mTOR inhibitors. All PDX expressed AR with varying intensities. GR and AR were co-expressed in the ER + tumors and in 3 TN PDX. We report the first PDX originated from South American countries that were genetically and biologically characterized and may be used in precision medicine studies. PDX expressing AR and/or GR are powerful tools to evaluate different endocrine treatment combinations even in TN tumors.https://doi.org/10.1038/s41598-025-86389-xBreast cancerPDXAncestryWhole exome-SeqTissue culturesAndrogen receptors |
| spellingShingle | Gabriela Pataccini Andrés Elia Gonzalo Sequeira Luisa Ambrosio Marcela Coianis Caroline A. Lamb Paola A. Rojas Paula Martínez Vázquez Javier Burruchaga Eunice Spengler Silvia I. Vanzulli Martin Abba Claudia Lanari Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country Scientific Reports Breast cancer PDX Ancestry Whole exome-Seq Tissue cultures Androgen receptors |
| title | Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country |
| title_full | Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country |
| title_fullStr | Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country |
| title_full_unstemmed | Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country |
| title_short | Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country |
| title_sort | steroid hormone receptors exome sequencing and treatment responsiveness of breast cancer patient derived xenografts originated in a south american country |
| topic | Breast cancer PDX Ancestry Whole exome-Seq Tissue cultures Androgen receptors |
| url | https://doi.org/10.1038/s41598-025-86389-x |
| work_keys_str_mv | AT gabrielapataccini steroidhormonereceptorsexomesequencingandtreatmentresponsivenessofbreastcancerpatientderivedxenograftsoriginatedinasouthamericancountry AT andreselia steroidhormonereceptorsexomesequencingandtreatmentresponsivenessofbreastcancerpatientderivedxenograftsoriginatedinasouthamericancountry AT gonzalosequeira steroidhormonereceptorsexomesequencingandtreatmentresponsivenessofbreastcancerpatientderivedxenograftsoriginatedinasouthamericancountry AT luisaambrosio steroidhormonereceptorsexomesequencingandtreatmentresponsivenessofbreastcancerpatientderivedxenograftsoriginatedinasouthamericancountry AT marcelacoianis steroidhormonereceptorsexomesequencingandtreatmentresponsivenessofbreastcancerpatientderivedxenograftsoriginatedinasouthamericancountry AT carolinealamb steroidhormonereceptorsexomesequencingandtreatmentresponsivenessofbreastcancerpatientderivedxenograftsoriginatedinasouthamericancountry AT paolaarojas steroidhormonereceptorsexomesequencingandtreatmentresponsivenessofbreastcancerpatientderivedxenograftsoriginatedinasouthamericancountry AT paulamartinezvazquez steroidhormonereceptorsexomesequencingandtreatmentresponsivenessofbreastcancerpatientderivedxenograftsoriginatedinasouthamericancountry AT javierburruchaga steroidhormonereceptorsexomesequencingandtreatmentresponsivenessofbreastcancerpatientderivedxenograftsoriginatedinasouthamericancountry AT eunicespengler steroidhormonereceptorsexomesequencingandtreatmentresponsivenessofbreastcancerpatientderivedxenograftsoriginatedinasouthamericancountry AT silviaivanzulli steroidhormonereceptorsexomesequencingandtreatmentresponsivenessofbreastcancerpatientderivedxenograftsoriginatedinasouthamericancountry AT martinabba steroidhormonereceptorsexomesequencingandtreatmentresponsivenessofbreastcancerpatientderivedxenograftsoriginatedinasouthamericancountry AT claudialanari steroidhormonereceptorsexomesequencingandtreatmentresponsivenessofbreastcancerpatientderivedxenograftsoriginatedinasouthamericancountry |